KR100611854B1 - 신경 펩타이드 ｙ(ｎｐｙ) 수용체 길항제로서의 티아졸유도체 - Google Patents
신경 펩타이드 ｙ(ｎｐｙ) 수용체 길항제로서의 티아졸유도체 Download PDFInfo
- Publication number
- KR100611854B1 KR100611854B1 KR1020047013315A KR20047013315A KR100611854B1 KR 100611854 B1 KR100611854 B1 KR 100611854B1 KR 1020047013315 A KR1020047013315 A KR 1020047013315A KR 20047013315 A KR20047013315 A KR 20047013315A KR 100611854 B1 KR100611854 B1 KR 100611854B1
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- thiazol
- ylamino
- benzoyl
- propyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- ASJLBFWOCHGXBO-UHFFFAOYSA-N CC(C)(C)OC(NCCCCCN=S)=O Chemical compound CC(C)(C)OC(NCCCCCN=S)=O ASJLBFWOCHGXBO-UHFFFAOYSA-N 0.000 description 1
- ZMZRUMCPNAJPPN-OQLLNIDSSA-N CC(C)(C)OC(NCCCNC(/N=C/N(C)C)=S)=O Chemical compound CC(C)(C)OC(NCCCNC(/N=C/N(C)C)=S)=O ZMZRUMCPNAJPPN-OQLLNIDSSA-N 0.000 description 1
- MCXNPYKTIYZKRN-UHFFFAOYSA-N CC(C)(C)OC(NCCNc1ncc(C(c2c(C)cccc2)=O)[s]1)=O Chemical compound CC(C)(C)OC(NCCNc1ncc(C(c2c(C)cccc2)=O)[s]1)=O MCXNPYKTIYZKRN-UHFFFAOYSA-N 0.000 description 1
- NMMKMDDAVQJVGL-UHFFFAOYSA-N CCS(NCCCNc1ncc(C(c2c(C)cccc2)=O)[s]1)(=O)=O Chemical compound CCS(NCCCNc1ncc(C(c2c(C)cccc2)=O)[s]1)(=O)=O NMMKMDDAVQJVGL-UHFFFAOYSA-N 0.000 description 1
- XQOKYIVYUQSLAC-FRKPEAEDSA-N Cc1c(C(c2cnc(/N=C/CCN)[s]2)=O)nccc1 Chemical compound Cc1c(C(c2cnc(/N=C/CCN)[s]2)=O)nccc1 XQOKYIVYUQSLAC-FRKPEAEDSA-N 0.000 description 1
- WUPWWMXYQFNPOB-UHFFFAOYSA-N Cc1ccccc1C(c1cnc(NCCCNC)[s]1)=O Chemical compound Cc1ccccc1C(c1cnc(NCCCNC)[s]1)=O WUPWWMXYQFNPOB-UHFFFAOYSA-N 0.000 description 1
- HXSYGKICCSRBIB-UHFFFAOYSA-N NCCCCCNc1ncc(C(c2ccncc2)=O)[s]1 Chemical compound NCCCCCNc1ncc(C(c2ccncc2)=O)[s]1 HXSYGKICCSRBIB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02004296.6 | 2002-02-28 | ||
| EP02004296 | 2002-02-28 | ||
| PCT/EP2003/001667 WO2003072577A1 (en) | 2002-02-28 | 2003-02-19 | Thiazole derivatives as npy receptor antagonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20040094735A KR20040094735A (ko) | 2004-11-10 |
| KR100611854B1 true KR100611854B1 (ko) | 2006-08-11 |
Family
ID=27763338
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020047013315A Expired - Fee Related KR100611854B1 (ko) | 2002-02-28 | 2003-02-19 | 신경 펩타이드 ｙ(ｎｐｙ) 수용체 길항제로서의 티아졸유도체 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6686381B2 (https=) |
| EP (1) | EP1480976B1 (https=) |
| JP (1) | JP2005526732A (https=) |
| KR (1) | KR100611854B1 (https=) |
| CN (1) | CN100363362C (https=) |
| AR (1) | AR038704A1 (https=) |
| AT (1) | ATE373654T1 (https=) |
| AU (1) | AU2003210305B2 (https=) |
| BR (1) | BR0308108A (https=) |
| CA (1) | CA2475299A1 (https=) |
| DE (1) | DE60316411T2 (https=) |
| ES (1) | ES2292992T3 (https=) |
| GT (1) | GT200300045A (https=) |
| MX (1) | MXPA04008379A (https=) |
| PA (1) | PA8567301A1 (https=) |
| PE (1) | PE20030930A1 (https=) |
| PL (1) | PL372463A1 (https=) |
| RU (1) | RU2004129285A (https=) |
| TW (1) | TW200403995A (https=) |
| UY (1) | UY27689A1 (https=) |
| WO (1) | WO2003072577A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7202257B2 (en) | 2003-12-24 | 2007-04-10 | Deciphera Pharmaceuticals, Llc | Anti-inflammatory medicaments |
| US7279576B2 (en) | 2002-12-31 | 2007-10-09 | Deciphera Pharmaceuticals, Llc | Anti-cancer medicaments |
| US7144911B2 (en) | 2002-12-31 | 2006-12-05 | Deciphera Pharmaceuticals Llc | Anti-inflammatory medicaments |
| RU2006107444A (ru) | 2003-08-12 | 2007-09-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | 2-амино-5-бензоилтиазолы в качестве антагонистов npy |
| CN100393718C (zh) * | 2003-08-12 | 2008-06-11 | 霍夫曼-拉罗奇有限公司 | 作为npy拮抗剂的噻唑衍生物 |
| CA2547804A1 (en) * | 2003-12-08 | 2005-06-30 | F. Hoffmann-La Roche Ag | Novel thiazole derivatives |
| NZ550114A (en) * | 2004-04-20 | 2011-02-25 | Transtech Pharma Inc | Substituted thiazole and pyrimidine derivatives as melanocortin receptor modulators |
| FR2884516B1 (fr) * | 2005-04-15 | 2007-06-22 | Cerep Sa | Antagonistes npy, preparation et utilisations |
| MY149143A (en) * | 2006-01-18 | 2013-07-15 | Amgen Inc | Thiazole compounds as protien kinase b (pkb) inhibitors |
| WO2010098298A1 (ja) * | 2009-02-27 | 2010-09-02 | 塩野義製薬株式会社 | 栄養素の消化吸収抑制作用を有する化合物とシクロヘキサンカルボキサミド誘導体を組み合わせてなる医薬組成物 |
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| KR102708177B1 (ko) | 2018-01-31 | 2024-09-23 | 데시페라 파마슈티칼스, 엘엘씨. | 위장관 기질 종양의 치료를 위한 병용 요법 |
| IL276398B2 (en) | 2018-01-31 | 2026-03-01 | Deciphera Pharmaceuticals Llc | Combination therapy for mastocytosis |
| EP3938363A1 (en) | 2019-03-11 | 2022-01-19 | Teva Pharmaceuticals International GmbH | Solid state forms of ripretinib |
| LT4013412T (lt) | 2019-08-12 | 2026-03-25 | Deciphera Pharmaceuticals, Llc | Ripretinibas, skirtas virškinamojo trakto stromos navikų gydymui |
| PT4013412T (pt) | 2019-08-12 | 2026-03-18 | Deciphera Pharmaceuticals Llc | Ripretinib para o tratamento de tumores estromais gastrointestinais |
| CN115243681B (zh) | 2019-12-30 | 2024-08-16 | 德西费拉制药有限责任公司 | 1-(4-溴-5-(1-乙基-7-(甲氨基)-2-侧氧基-1,2-二氢-1,6-萘啶-3-基)-2-氟苯基)-3-苯基脲的组合物 |
| HRP20231699T1 (hr) | 2019-12-30 | 2024-05-10 | Deciphera Pharmaceuticals, Llc | Formulacije inhibitora amorfne kinaze i postupci njihove primjene |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247547A (en) * | 1983-06-22 | 1988-12-28 | Paul Hadvary | Leucine derivatives |
| CA1270837A (en) | 1984-12-21 | 1990-06-26 | Hoffmann-La Roche Limited | Oxetanones |
| CA1328881C (en) | 1984-12-21 | 1994-04-26 | Pierre Barbier | Process for the manufacture of oxetanones |
| CA2035972C (en) | 1990-02-23 | 2006-07-11 | Martin Karpf | Process for the preparation of oxetanones |
| US5274143A (en) | 1991-07-23 | 1993-12-28 | Hoffmann-La Roche Inc. | Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione |
| AUPN163795A0 (en) | 1995-03-10 | 1995-04-06 | DIPNALL, David | A device for extracting energy from moving water particles |
| US6004996A (en) | 1997-02-05 | 1999-12-21 | Hoffman-La Roche Inc. | Tetrahydrolipstatin containing compositions |
| US6267952B1 (en) | 1998-01-09 | 2001-07-31 | Geltex Pharmaceuticals, Inc. | Lipase inhibiting polymers |
| DE19824175A1 (de) * | 1998-05-29 | 1999-12-02 | Novartis Ag | Amino-azol-Verbindungen |
| PT1105123E (pt) | 1998-08-14 | 2004-08-31 | Hoffmann La Roche | Composicoes farmaceuticas contendo inibidores da lipase e quitosano |
| TR200100471T2 (tr) | 1998-08-14 | 2001-07-23 | F.Hoffmann-La Roche Ag | Lipaz inhibitörleri içeren farmasötik bileşimler |
| US20010039275A1 (en) * | 2000-02-04 | 2001-11-08 | Bowler Andrew Neil | Use of 2,4-diaminothiazole derivatives |
| AU2001246494A1 (en) * | 2000-03-03 | 2001-09-12 | Novartis Ag | Condensed thiazolamines and their use as neuropeptide y5 antagonists |
| MXPA04000906A (es) * | 2001-08-03 | 2004-11-22 | Novo Nordisk As | Nuevos derivados de 2,4-diaminotiazol. |
-
2003
- 2003-02-19 KR KR1020047013315A patent/KR100611854B1/ko not_active Expired - Fee Related
- 2003-02-19 JP JP2003571283A patent/JP2005526732A/ja active Pending
- 2003-02-19 BR BR0308108-7A patent/BR0308108A/pt not_active IP Right Cessation
- 2003-02-19 DE DE60316411T patent/DE60316411T2/de not_active Expired - Fee Related
- 2003-02-19 RU RU2004129285/04A patent/RU2004129285A/ru not_active Application Discontinuation
- 2003-02-19 PL PL03372463A patent/PL372463A1/xx not_active Application Discontinuation
- 2003-02-19 CN CNB03804823XA patent/CN100363362C/zh not_active Expired - Fee Related
- 2003-02-19 MX MXPA04008379A patent/MXPA04008379A/es active IP Right Grant
- 2003-02-19 WO PCT/EP2003/001667 patent/WO2003072577A1/en not_active Ceased
- 2003-02-19 AT AT03742945T patent/ATE373654T1/de not_active IP Right Cessation
- 2003-02-19 CA CA002475299A patent/CA2475299A1/en not_active Abandoned
- 2003-02-19 EP EP03742945A patent/EP1480976B1/en not_active Expired - Lifetime
- 2003-02-19 AU AU2003210305A patent/AU2003210305B2/en not_active Ceased
- 2003-02-19 ES ES03742945T patent/ES2292992T3/es not_active Expired - Lifetime
- 2003-02-25 PA PA20038567301A patent/PA8567301A1/es unknown
- 2003-02-25 PE PE2003000182A patent/PE20030930A1/es not_active Application Discontinuation
- 2003-02-26 AR ARP030100627A patent/AR038704A1/es not_active Application Discontinuation
- 2003-02-26 US US10/374,573 patent/US6686381B2/en not_active Expired - Fee Related
- 2003-02-26 GT GT200300045A patent/GT200300045A/es unknown
- 2003-02-26 TW TW092104045A patent/TW200403995A/zh unknown
- 2003-02-27 UY UY27689A patent/UY27689A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005526732A (ja) | 2005-09-08 |
| CN1639158A (zh) | 2005-07-13 |
| EP1480976A1 (en) | 2004-12-01 |
| ATE373654T1 (de) | 2007-10-15 |
| PE20030930A1 (es) | 2003-11-08 |
| AR038704A1 (es) | 2005-01-26 |
| AU2003210305B2 (en) | 2006-07-06 |
| EP1480976B1 (en) | 2007-09-19 |
| KR20040094735A (ko) | 2004-11-10 |
| AU2003210305A1 (en) | 2003-09-09 |
| DE60316411D1 (de) | 2007-10-31 |
| CN100363362C (zh) | 2008-01-23 |
| US6686381B2 (en) | 2004-02-03 |
| TW200403995A (en) | 2004-03-16 |
| RU2004129285A (ru) | 2005-10-27 |
| BR0308108A (pt) | 2004-12-07 |
| GT200300045A (es) | 2003-09-23 |
| US20030225141A1 (en) | 2003-12-04 |
| UY27689A1 (es) | 2003-08-29 |
| PA8567301A1 (es) | 2004-02-07 |
| WO2003072577A1 (en) | 2003-09-04 |
| ES2292992T3 (es) | 2008-03-16 |
| DE60316411T2 (de) | 2008-06-12 |
| CA2475299A1 (en) | 2003-09-04 |
| MXPA04008379A (es) | 2004-11-26 |
| PL372463A1 (en) | 2005-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100611854B1 (ko) | 신경 펩타이드 ｙ(ｎｐｙ) 수용체 길항제로서의 티아졸유도체 | |
| EP1194421B1 (en) | Selective npy (y5) antagonists | |
| US7189720B2 (en) | Selective NPY (Y5) antagonists | |
| US6218408B1 (en) | Selective NPY (Y5) antagonists (bicyclics) | |
| CZ207298A3 (cs) | Fenylthiazolové deriváty, způsob výroby a farmaceutický prostředek | |
| US7253197B2 (en) | Aminothiazole derivatives | |
| CN100422179C (zh) | 2-氨基-5-苯甲酰基噻唑npy拮抗剂 | |
| US6225330B1 (en) | Selective NPY (Y5) antagonists (tricyclics) | |
| US7273880B2 (en) | Selective NPY (Y5) antagonists | |
| JP2002528442A (ja) | チアゾール誘導体 | |
| US6989379B1 (en) | Selective NPY (Y5) antagonists | |
| KR100679777B1 (ko) | 싸이아졸 유도체 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| R15-X000 | Change to inventor requested |
St.27 status event code: A-3-3-R10-R15-oth-X000 |
|
| R16-X000 | Change to inventor recorded |
St.27 status event code: A-3-3-R10-R16-oth-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
St.27 status event code: A-1-2-D10-D22-exm-PE0701 |
|
| PR1002 | Payment of registration fee |
St.27 status event code: A-2-2-U10-U12-oth-PR1002 Fee payment year number: 1 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
St.27 status event code: A-2-4-F10-F11-exm-PR0701 |
|
| PG1601 | Publication of registration |
St.27 status event code: A-4-4-Q10-Q13-nap-PG1601 |
|
| LAPS | Lapse due to unpaid annual fee | ||
| PC1903 | Unpaid annual fee |
St.27 status event code: A-4-4-U10-U13-oth-PC1903 Not in force date: 20090805 Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE |
|
| PC1903 | Unpaid annual fee |
St.27 status event code: N-4-6-H10-H13-oth-PC1903 Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE Not in force date: 20090805 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-5-5-R10-R18-oth-X000 |